Cargando…
Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series
BACKGROUND: Teprotumumab is a novel treatment that reduces inflammation and symptoms caused by thyroid eye disease. There are limited data on teprotumumab’s effect on intraocular pressure. CASE PRESENTATION: We report nine patients diagnosed with thyroid eye disease whose intraocular pressure decrea...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087984/ https://www.ncbi.nlm.nih.gov/pubmed/35538553 http://dx.doi.org/10.1186/s13256-022-03375-x |
_version_ | 1784704273319198720 |
---|---|
author | Chu, Matthew Sung, Jonathan Song, Michael Song, Alice Song, Julia |
author_facet | Chu, Matthew Sung, Jonathan Song, Michael Song, Alice Song, Julia |
author_sort | Chu, Matthew |
collection | PubMed |
description | BACKGROUND: Teprotumumab is a novel treatment that reduces inflammation and symptoms caused by thyroid eye disease. There are limited data on teprotumumab’s effect on intraocular pressure. CASE PRESENTATION: We report nine patients diagnosed with thyroid eye disease whose intraocular pressure decreased during teprotumumab treatment for 8 weeks: patient 1, a 67-year-old Hispanic woman; patient 2, an 86-year-old African-American man; patient 3, a 71-year-old Caucasian woman; patient 4, a 72-year-old Hispanic woman; patient 5, a 65-year-old Caucasian woman; patient 6, a 54-year-old Caucasian man; patient 7, a 54-year-old Asian man; patient 8, a 31-year-old Asian woman; patient 9, a 60-year-old Caucasian woman. The diagnosis of thyroid eye disease was based on increased redness, swelling, and excessive tearing; abnormal proptosis, lid retraction, and diplopia measurements were also taken during physical examination. Intraocular pressure in primary, lateral gaze, and upgaze was documented. There was significant (p = 0.0397) improvement of primary gaze eye pressure from pre-teprotumumab infusions (baseline) to completion of the treatment course. CONCLUSIONS: Teprotumumab significantly decreased the intraocular pressure for patients during the duration of the study. Teprotumumab is a novel medication that is approved for the primary treatment of thyroid eye disease in both acute and chronic thyroid eye disease. Previous treatments used to treat thyroid eye disease include glucocorticoids, radiotherapy, or orbital decompression surgery; however, these treatments all have significant limitations. Teprotumumab is an effective noninvasive alternative for decreasing symptoms of thyroid eye disease and, as shown, also lowers intraocular pressure. However, teprotumumab should not be used as a substitute for glaucoma medications; its ability to lower intraocular pressure may be in addition to lowering periorbital pressure and retro-orbital pressure. |
format | Online Article Text |
id | pubmed-9087984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90879842022-05-11 Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series Chu, Matthew Sung, Jonathan Song, Michael Song, Alice Song, Julia J Med Case Rep Case Report BACKGROUND: Teprotumumab is a novel treatment that reduces inflammation and symptoms caused by thyroid eye disease. There are limited data on teprotumumab’s effect on intraocular pressure. CASE PRESENTATION: We report nine patients diagnosed with thyroid eye disease whose intraocular pressure decreased during teprotumumab treatment for 8 weeks: patient 1, a 67-year-old Hispanic woman; patient 2, an 86-year-old African-American man; patient 3, a 71-year-old Caucasian woman; patient 4, a 72-year-old Hispanic woman; patient 5, a 65-year-old Caucasian woman; patient 6, a 54-year-old Caucasian man; patient 7, a 54-year-old Asian man; patient 8, a 31-year-old Asian woman; patient 9, a 60-year-old Caucasian woman. The diagnosis of thyroid eye disease was based on increased redness, swelling, and excessive tearing; abnormal proptosis, lid retraction, and diplopia measurements were also taken during physical examination. Intraocular pressure in primary, lateral gaze, and upgaze was documented. There was significant (p = 0.0397) improvement of primary gaze eye pressure from pre-teprotumumab infusions (baseline) to completion of the treatment course. CONCLUSIONS: Teprotumumab significantly decreased the intraocular pressure for patients during the duration of the study. Teprotumumab is a novel medication that is approved for the primary treatment of thyroid eye disease in both acute and chronic thyroid eye disease. Previous treatments used to treat thyroid eye disease include glucocorticoids, radiotherapy, or orbital decompression surgery; however, these treatments all have significant limitations. Teprotumumab is an effective noninvasive alternative for decreasing symptoms of thyroid eye disease and, as shown, also lowers intraocular pressure. However, teprotumumab should not be used as a substitute for glaucoma medications; its ability to lower intraocular pressure may be in addition to lowering periorbital pressure and retro-orbital pressure. BioMed Central 2022-05-10 /pmc/articles/PMC9087984/ /pubmed/35538553 http://dx.doi.org/10.1186/s13256-022-03375-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Chu, Matthew Sung, Jonathan Song, Michael Song, Alice Song, Julia Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series |
title | Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series |
title_full | Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series |
title_fullStr | Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series |
title_full_unstemmed | Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series |
title_short | Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series |
title_sort | intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087984/ https://www.ncbi.nlm.nih.gov/pubmed/35538553 http://dx.doi.org/10.1186/s13256-022-03375-x |
work_keys_str_mv | AT chumatthew intraocularpressureimprovementinpatientsreceivingteprotumumabforthetreatmentofthyroideyediseaseacaseseries AT sungjonathan intraocularpressureimprovementinpatientsreceivingteprotumumabforthetreatmentofthyroideyediseaseacaseseries AT songmichael intraocularpressureimprovementinpatientsreceivingteprotumumabforthetreatmentofthyroideyediseaseacaseseries AT songalice intraocularpressureimprovementinpatientsreceivingteprotumumabforthetreatmentofthyroideyediseaseacaseseries AT songjulia intraocularpressureimprovementinpatientsreceivingteprotumumabforthetreatmentofthyroideyediseaseacaseseries |